Laddar...
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of...
Sparad:
| Huvudupphovsmän: | , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Dove Medical Press
2014
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3983075/ https://ncbi.nlm.nih.gov/pubmed/24741337 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PROM.S41768 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|